Actelion receives marketing approval for Opsumit (macitentan) in pulmonary...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 March 2015 - Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted marketing approval for Opsumit®...
View ArticleActelion receives Therapeutic Goods Administration (TGA) approval in...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 07 February 2014 - Actelion Ltd (SIX: ATLN) today announced the approval of Opsumit® (macitentan) 10 mg for the treatment of pulmonary arterial...
View ArticleActelion to present at upcoming investor conferences - Actelion 2015-2020 -...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 11 January 2016- Actelion Ltd (SIX: ATLN) announced today that representatives from Actelion will present at upcoming investor conferences....
View ArticleFurther data on selexipag (Uptravi) and macitentan (Opsumit) to be presented...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 September 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug...
View ArticleActelion receives Swissmedic approval for Uptravi (selexipag) for treatment...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 August 2016- Actelion Ltd (SIX: ATLN) announced today that Swissmedic has granted approval for the orally active, selective IP prostacyclin...
View ArticleActelion's Selexipag Meets Primary Endpoint
Actelion Ltd. (ALIOF) announced top-line data from the randomized, multi-center, double-blind, placebo-controlled phase III GRIPHON study (n=1,156) on selexipag for pulmonary arterial hypertension...
View ArticleActelion Using Combination Strategy to Attack Multiple Sclerosis
Actelion Ltd. is seeking more effective treatments for people suffering from multiple sclerosis by following a strategy that’s worked in treating HIV, cancer and heart failure -- combining medicines to...
View ArticleActelion obtains an option to in-license vamorolone from ReveraGen
Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side...
View ArticleActelion obtains an option to in-license vamorolone from ReveraGen (Actelion...
(Source: Actelion Ltd) Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without...
View ArticleNew scientific publications highlight the unique profile of Actelion's...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 17 October 2016 - Actelion Ltd (SIX: ATLN) announced today that a series of recently published scientific articles [1,2,3,4,5] describing the...
View ArticleEISAI INITIATES PHASE 2 CLINICAL TRIAL TO EVALUATE LEMBOREXANT IN THE...
(Source: Purdue Pharma LP) WOODCLIFF LAKE, N.J., and STAMFORD, Conn, Oct. 31, 2016 - Eisai and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study...
View ArticleActelion to investigate all-oral combination therapy for patients with...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 29 September 2016 - Actelion Ltd (SIX: ATLN) announced today that it will investigate the use of combination therapy with ponesimod and dimethyl...
View ArticleExcellent operational results - supported by outstanding Uptravi launch -...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 20 October 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first nine months of 2016. OPERATING HIGHLIGHTS Strong Opsumit...
View ArticleActelion completes first-line share purchase program (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL / BASEL, SWITZERLAND - 22 August 2016 - Actelion (SIX: ATLN) today announced that it completed its first-line share purchase program (initiated on 9 December 2013) on...
View ArticleACTELION STATEMENT (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 10 September 2015- Actelion Ltd (SIX: ATLN) confirmed today that it has initiated preliminary discussions with ZS Pharma, Inc. (ZSPH) without any...
View ArticleActelion issues invitation to 2016 Annual General Meeting of Shareholders...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 6 April 2016- Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of...
View ArticleActelion issues invitation to 2015 Annual General Meeting of Shareholders...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 10 April 2015- Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf...
View ArticleActelion's Annual General Meeting of Shareholders held in Basel, Switzerland...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2015 - At today's Annual General Meeting (AGM) of Actelion Ltd (SIX: ATLN), held in Basel, Switzerland, shareholders voted in favor of all...
View ArticleActelion announces commencement of share repurchase program (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 March 2015 - Actelion (SIX: ATLN) announced today that it has received approval from the relevant authorities to launch the repurchase of up to 10...
View ArticleActelion creates Vaxxilon together with the Max Planck Society (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic...
View Article